New research published in JAMA Network Open found that GLP-1 drugs are more effective in reducing the risk of 10 obesity-associated cancers in patients with type 2 diabetes compared to insulin or metformin. The study analyzed data from over 1.6 million patients from 2005 to 2018. GLP-1 drugs are known for their efficacy in weight loss and managing type 2 diabetes, prompting researchers to conduct the study. Rong Xu, a professor at Case Western Reserve University and study author, highlighted the potential benefits of GLP-1 drugs in reducing the risk of cancer in diabetic patients.
Source link
GLP-1s lower risk of 10 obesity-associated cancers, study shows
